查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2082160

慢性阻塞性肺病（COPD）治療市場：2026-2032年全球市場預測（按藥物類別、給藥途徑、治療階段、劑量方法、分銷管道和醫療保健服務環境分類）

Chronic Obstructive Pulmonary Disease Treatment Market by Drug Class, Route Of Administration, Therapy Line, Regimen Type, Distribution Channel, Care Setting - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，慢性阻塞性肺病(COPD) 治療市場將成長至 242.5 億美元，複合年成長率為 7.07%。

主要市場統計數據
基準年 2025 150.2億美元
預計年份：2026年 160.5億美元
預測年份 2032 242.5億美元
複合年成長率 (%) 7.07%

慢性阻塞性肺病（COPD）的治療正從控制症狀轉向基於精準醫療的預防性護理。 COPD仍然是全球主要死因之一，世界衛生組織（WHO）將其列為全球第三大死因，每年導致數百萬人死亡。吸煙、室內外空氣污染、職業性粉塵和煙霧、老化、反覆呼吸道感染疾病以及由於肺功能檢查不足導致的診斷延誤等因素，進一步加劇了COPD的負擔。

治療方案包括短效和長效支氣管擴張劑、針對特定患者的吸入性糖皮質激素、固定劑量複方吸入劑、磷酸二酯酶抑制劑、用於特定人群預防急性加重的抗生素、氧氣療法、肺部復健、疫苗接種、戒菸支持以及新型生物製藥和抗發炎療法。治療需求日益受到以下因素的影響：指南指導治療的逐步強化、實際應用中藥物依從性方面的挑戰、吸入器的易用性、保險公司的嚴格審查以及降低急性加重、住院率和死亡率的需求。

慢性阻塞性肺病治療的變革性變化

隨著GOLD指引的更新、雙聯療法（包括支氣管擴張治療）的廣泛應用，以及基於氣喘史、合併氣喘、肺炎風險和血清嗜酸性粒細胞計數等因素更精準地選擇吸入性糖皮質激素，慢性阻塞性肺病（COPD）的治療格局正在發生重塑。儘管三聯聯合治療在持續急性惡化的患者中臨床意義日益凸顯，但支氣管擴張治療仍是維持治療的核心，有助於改善肺功能、呼吸困難、運動耐受性和生活品質。

人工智慧對慢性阻塞性肺病治療的累積影響

人工智慧 (AI) 透過改善疾病檢測、風險分層和照護協調，正累積提升慢性阻塞性肺病 (COPD) 的治療效果。利用 AI 分析電子健康記錄、藥物計費數據、肺功能測量數據、脈搏血氧計數據、穿戴式裝置數據和影像數據，可以識別未確診的患者，預測病情加重風險，並及早發現藥物依從性下降的情況。這些工具尤其重要，因為 COPD 往往確診較晚，而病情加重會導致肺功能迅速下降、反覆住院以及死亡風險增加。

關鍵區域洞察

北美是慢性阻塞性肺病（COPD）治療的重要區域，這得益於品牌吸入器、生物製藥、數位化呼吸護理以及基於指南的慢性病管理的廣泛應用。在美國，COPD確診患者數量龐大，急性加重導致的住院費用高昂，且保險公司的影響顯著；而在加拿大，公共醫療保險報銷、戒菸支持、疫苗接種和整合式基層醫療路徑則更為重要。歐洲的特點是呼吸系統疾病指南成熟、肺部復健模式完善、空氣品質法規完善以及集中式成本效益評估；而在德國、法國、義大利、西班牙和英國，醫療保健服務的可及性則取決於國家和地區的醫療保險報銷系統。

關鍵小組洞察

歐盟持續透過循證報銷機制、衛生技術評估、空氣品質政策、菸草控制措施和統一的監管標準影響慢性阻塞性肺病（COPD）的治療。七國集團（G7）正透過先進的臨床研究生態系統、生物製藥和數位醫療的高普及率、成熟的支付方框架以及強大的真實世界證據（REW）利用能力推動創新。同時，北約成員國的市場與高所得醫療保健系統高度重合，這些系統優先考慮呼吸系統疾病的應對能力、供應連續性、基本藥物的可及性以及慢性病的應對準備。

主要國家的概況

美國擁有廣泛的專家網路和以支付方為主導的治療路徑，在先進慢性阻塞性肺病（COPD）治療藥物的商業化方面發揮著主導作用，這些藥物包括新型吸入藥物、三聯聯合治療、支持用藥依從性的數位化解決方案以及適用於合格患者的生物製藥。加拿大與指南和公共保險路徑保持高度一致，而墨西哥和巴西則面臨著對經濟有效的吸入療法、擴大肺功能檢測範圍以及改進基層醫療早期篩檢系統的需求不斷成長。在歐洲，英國、德國、法國、義大利和西班牙仍然是循證COPD管理實施的核心，但報銷標準、處方規定、衛生技術評估結果以及區域醫療保健預算正在影響治療的順序和可及性。

為行業領導者提供的實用建議

產業領導者應優先考慮差異化的臨床價值，包括減少急性惡化、控制症狀、提高用藥依從性和安全性。產品系列策略應與基於GOLD指南的治療聯合治療、基於表現型的抗發炎藥物使用，以及在合格的嗜酸性粒細胞阻塞性肺病（COPD）患者群體中使用生物製藥。領導者還應投資於吸入器的易用性、劑量計數器、病患教育、用藥依從性支援服務，以及能夠證明減少住院次數、減少嚴重急性加重和改善健康相關生活品質的證據。

調查方法

本執行摘要基於系統性的調查方法，該方法結合了二次調查、一次檢驗和資料檢驗。主要證據來源包括世界衛生組織流行病學數據、GOLD戰略報告、監管標籤和批准資訊、同行評審的臨床試驗、真實世界數據（REW）研究、衛生技術評估（HTA）文件、國家呼吸系統疾病指南、醫院利用數據、公共衛生資料集以及公開的保險公司政策。

結論

慢性阻塞性肺病（COPD）治療市場正進入一個新階段，其特點是精準的表現型分析、新型抗發炎機制、數位化驅動的醫療服務以及對預防急性惡化的日益重視。儘管支氣管擴張劑和聯合吸入藥物仍是治療的基礎，生物製藥、吸入非類固醇抗發炎藥、肺部復健、疫苗接種以及人工智慧驅動的醫療模式正在拓展臨床和商業性機會。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章慢性阻塞性肺病（COPD）治療市場：依藥物類別分類

  • 抗膽鹼能藥物
  • BETA-激動劑
  • 皮質類固醇
  • 甲基黃嘌呤類衍生物

第8章：慢性阻塞性肺病（COPD）治療市場：依給藥途徑分類

  • 鼻腔
  • 靜脈
  • 口服

第9章：慢性阻塞性肺病（COPD）治療市場：依治療線分類

  • 一線治療
  • 二級治療
  • 從第三線開始治療

第10章：慢性阻塞性肺病（COPD）治療市場：依治療類型分類

  • 單藥治療
  • 聯合治療

第11章：慢性阻塞性肺病（COPD）治療市集：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章：慢性阻塞性肺病（COPD）治療市場：依護理環境分類

  • 住院治療
  • 門診治療
  • 居家照護

第13章：慢性阻塞性肺病（COPD）治療市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章慢性阻塞性肺病（COPD）治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：慢性阻塞性肺病（COPD）治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Adherium Limited
  • AptarGroup, Inc.
  • Arcede Pharma AB
  • AstraZeneca PLC
  • Aurobindo Pharma Ltd.
  • Boehringer Ingelheim International GmbH
  • Chiesi Farmaceutici SpA
  • Cipla Ltd.
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Ltd.
  • Grifols, SA
  • Hikma Pharmaceuticals PLC
  • Iconovo AB
  • Innoviva, Inc.
  • Inogen, Inc.
  • Invacare Corporation
  • Kamada Ltd.
  • Kindeva Drug Delivery
  • Koninklijke Philips NV
  • Lupin Limited
  • Medline Industries, LP
  • Merck & Co., Inc.
  • Mylan NV
  • Nidek Medical Products, Inc.
  • Novartis AG
  • Orion Corporation
  • PARI Pharma GmbH
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-43676CF42C41

The Chronic Obstructive Pulmonary Disease Treatment Market is projected to grow by USD 24.25 billion at a CAGR of 7.07% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 15.02 billion
Estimated Year [2026] USD 16.05 billion
Forecast Year [2032] USD 24.25 billion
CAGR (%) 7.07%

Chronic obstructive pulmonary disease treatment is moving from symptom control toward precision-guided, prevention-oriented care. COPD remains one of the world's leading causes of death, with the World Health Organization identifying it as the third leading cause of mortality globally and attributing millions of deaths annually to the disease. The burden is amplified by tobacco exposure, household and ambient air pollution, occupational dusts and fumes, aging populations, recurrent respiratory infections, and delayed diagnosis due to underuse of spirometry.

The treatment landscape includes short- and long-acting bronchodilators, inhaled corticosteroids for selected patients, fixed-dose combination inhalers, phosphodiesterase inhibitors, antibiotics for exacerbation prevention in defined populations, oxygen therapy, pulmonary rehabilitation, vaccination, smoking cessation, and emerging biologic and anti-inflammatory approaches. Demand is increasingly shaped by guideline-based escalation, real-world adherence challenges, inhaler device usability, payer scrutiny, and the need to reduce acute exacerbations, hospitalizations, and mortality.

Transformative Shifts in COPD Care

The COPD treatment landscape is being reshaped by updated GOLD guidance, broader use of dual bronchodilation, and more selective use of inhaled corticosteroids based on exacerbation history, asthma overlap, pneumonia risk, and blood eosinophil counts. Triple therapy has gained clinical relevance for patients with persistent exacerbations, while maintenance bronchodilation remains central to improving lung function, dyspnea, exercise tolerance, and quality of life.

Innovation is also expanding beyond conventional inhalers. Recent regulatory approvals for novel mechanisms, including inhaled PDE3/PDE4 inhibition and biologic therapy for eosinophilic COPD, signal a shift toward phenotype-directed treatment. At the same time, payers and health systems are prioritizing adherence, inhaler technique education, pulmonary rehabilitation access, vaccination coverage, smoking cessation, and early diagnosis because these interventions are strongly linked to reduced exacerbation risk and lower avoidable healthcare utilization.

AI's Cumulative Impact on COPD Treatment

Artificial intelligence is cumulatively strengthening COPD treatment by improving detection, risk stratification, and care coordination. AI-enabled analysis of electronic health records, pharmacy claims, spirometry signals, pulse oximetry, wearables, and imaging can help identify undiagnosed patients, predict exacerbation risk, and flag declining adherence. These tools are especially relevant because COPD is frequently diagnosed late, and exacerbations are associated with accelerated lung function decline, repeated hospital admissions, and higher mortality risk.

AI is also influencing drug development and clinical strategy. Machine learning supports patient phenotyping, trial enrichment, inhaler-use analytics, digital companion apps, virtual pulmonary rehabilitation, and remote monitoring programs. However, adoption depends on clinical validation, interoperability, transparency, privacy safeguards, and equitable performance across age groups, smoking histories, ethnicities, sex, socioeconomic status, and comorbidity profiles. Industry leaders should treat AI as an evidence-generating layer that complements, rather than replaces, guideline-led clinical judgment.

Key Regional Insights

North America represents a high-value COPD treatment region due to strong uptake of branded inhalers, biologics, digital respiratory care, and guideline-based chronic disease management. The United States has a large diagnosed COPD population, high hospitalization costs from exacerbations, and extensive payer influence, while Canada emphasizes public reimbursement, smoking cessation, vaccination, and integrated primary care pathways. Europe is characterized by mature respiratory guidelines, established pulmonary rehabilitation models, air-quality regulation, and centralized cost-effectiveness assessment, with Germany, France, Italy, Spain, and the United Kingdom shaping access decisions through national and regional reimbursement systems.

Asia-Pacific is the fastest-evolving opportunity base because of aging demographics, high tobacco exposure in several markets, biomass fuel exposure, urban air pollution, and expanding access to respiratory diagnostics in China, India, Japan, South Korea, Australia, and ASEAN economies. Latin America, led by Brazil and Mexico, faces high underdiagnosis and uneven specialist access but shows rising demand for affordable combination inhalers and primary care-based respiratory management. The Middle East, including GCC countries, is investing in specialty care capacity, digital health infrastructure, and hospital-based respiratory services, while Africa remains constrained by diagnosis gaps, medicine affordability, limited spirometry availability, and competing infectious respiratory burdens.

Key Group Insights

The European Union continues to influence COPD treatment through evidence-based reimbursement, health technology assessment, air-quality policy, tobacco control measures, and harmonized regulatory standards. G7 countries drive innovation through advanced clinical research ecosystems, higher biologic and digital health adoption, mature payer frameworks, and strong real-world evidence capabilities, while NATO markets overlap substantially with high-income systems that prioritize respiratory resilience, supply continuity, essential medicine access, and chronic disease preparedness.

BRICS countries represent a major patient-access opportunity because China, India, Brazil, Russia, and South Africa combine large populations with substantial exposure to smoking, pollution, biomass fuel, and occupational risk factors. ASEAN markets are expanding through urban hospital networks, greater use of inhaled maintenance therapies, improving respiratory diagnostics, and public health initiatives against tobacco. GCC countries are advancing specialist respiratory services, integrated electronic health records, and digital health infrastructure, but long-term success depends on earlier diagnosis, adherence support, affordability, smoking prevention, and broader access to pulmonary rehabilitation.

Key Country Insights

The United States leads in commercialization of advanced COPD therapies, including novel inhaled medicines, triple combinations, digital adherence solutions, and biologics for eligible patients, supported by extensive specialist networks and payer-managed treatment pathways. Canada maintains strong guideline alignment and public reimbursement pathways, while Mexico and Brazil show growing demand for cost-effective inhaled therapies, expanded spirometry access, and improved primary care detection. In Europe, the United Kingdom, Germany, France, Italy, and Spain remain central to adoption of evidence-based COPD management, although reimbursement criteria, prescribing controls, health technology assessment outcomes, and regional health budgets shape therapy sequencing and access.

China and India are pivotal COPD treatment countries due to large patient pools, air pollution exposure, smoking-related disease, biomass exposure, and expanding healthcare access, but underdiagnosis and uneven spirometry use remain substantial barriers. Japan, South Korea, and Australia demonstrate advanced respiratory care models, high standards for inhaler quality, aging-population management, vaccination integration, and growing use of digital monitoring. Russia presents demand for maintenance inhalers, exacerbation prevention, and hospital-based respiratory care, though access can vary by region, procurement structure, and reimbursement coverage.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated clinical value in exacerbation reduction, symptom control, adherence improvement, and safety. Portfolio strategies should align with GOLD-guided treatment pathways, including dual bronchodilation, appropriate triple therapy, phenotype-based use of anti-inflammatory agents, and biologics for eligible eosinophilic COPD populations. Leaders should also invest in inhaler usability, dose counters, patient education, adherence services, and evidence demonstrating fewer hospitalizations, fewer severe exacerbations, and better health-related quality of life.

Commercial success will depend on pairing medicines with services that solve real-world barriers. Recommended actions include expanding spirometry partnerships, supporting smoking cessation and vaccination programs, building AI-enabled risk identification tools, generating local health economic evidence, strengthening pharmacovigilance, and improving access to pulmonary rehabilitation. In emerging markets, affordability, device simplicity, physician training, reliable distribution, and local guideline alignment are critical to sustainable growth.

Research Methodology

This executive summary is built on a structured methodology combining secondary research, primary validation, and data triangulation. Core evidence sources include WHO epidemiology, GOLD strategy reports, regulatory labels and approvals, peer-reviewed clinical trials, real-world evidence studies, health technology assessment documents, national respiratory guidelines, hospital utilization data, public health datasets, and publicly available payer policies.

Market interpretation integrates therapy class assessment, disease burden analysis, pipeline evaluation, reimbursement review, regional access mapping, treatment pathway assessment, and expert-informed validation. Findings are cross-checked across clinical, regulatory, commercial, and public health sources to avoid unsupported claims. The methodology emphasizes verified insights over speculative market sizing, enabling decision-makers to connect COPD treatment trends with evidence-based investment, access, and commercialization priorities.

Conclusion

The COPD treatment market is entering a new phase defined by precision phenotyping, novel anti-inflammatory mechanisms, digitally enabled care, and stronger emphasis on preventing exacerbations. While bronchodilators and combination inhalers remain the foundation of treatment, biologics, inhaled non-steroidal anti-inflammatory therapies, pulmonary rehabilitation, vaccination, and AI-supported care models are broadening the clinical and commercial opportunity.

Sustainable leadership will require more than product innovation. Companies that combine robust clinical evidence, affordability strategies, patient-centered inhaler design, adherence support, real-world data generation, and regional access expertise will be best positioned to improve outcomes. As health systems intensify focus on chronic respiratory disease, COPD treatment will remain a strategic priority across pharmaceuticals, devices, diagnostics, and digital health.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Chronic Obstructive Pulmonary Disease Treatment Market, by Drug Class

  • 7.1. Anticholinergics
  • 7.2. Beta Agonists
  • 7.3. Corticosteroids
  • 7.4. Methylxanthines

8. Chronic Obstructive Pulmonary Disease Treatment Market, by Route Of Administration

  • 8.1. Nasal
  • 8.2. Intravenous
  • 8.3. Oral

9. Chronic Obstructive Pulmonary Disease Treatment Market, by Therapy Line

  • 9.1. First-Line Therapy
  • 9.2. Second-Line Therapy
  • 9.3. Third-Line And Later Therapy

10. Chronic Obstructive Pulmonary Disease Treatment Market, by Regimen Type

  • 10.1. Monotherapy
  • 10.2. Dual Therapy

11. Chronic Obstructive Pulmonary Disease Treatment Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Chronic Obstructive Pulmonary Disease Treatment Market, by Care Setting

  • 12.1. Inpatient Care
  • 12.2. Outpatient Care
  • 12.3. Homecare

13. Chronic Obstructive Pulmonary Disease Treatment Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Chronic Obstructive Pulmonary Disease Treatment Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Chronic Obstructive Pulmonary Disease Treatment Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Adherium Limited
  • 17.2. AptarGroup, Inc.
  • 17.3. Arcede Pharma AB
  • 17.4. AstraZeneca PLC
  • 17.5. Aurobindo Pharma Ltd.
  • 17.6. Boehringer Ingelheim International GmbH
  • 17.7. Chiesi Farmaceutici S.p.A.
  • 17.8. Cipla Ltd.
  • 17.9. GlaxoSmithKline plc
  • 17.10. Glenmark Pharmaceuticals Ltd.
  • 17.11. Grifols, S.A.
  • 17.12. Hikma Pharmaceuticals PLC
  • 17.13. Iconovo AB
  • 17.14. Innoviva, Inc.
  • 17.15. Inogen, Inc.
  • 17.16. Invacare Corporation
  • 17.17. Kamada Ltd.
  • 17.18. Kindeva Drug Delivery
  • 17.19. Koninklijke Philips N.V.
  • 17.20. Lupin Limited
  • 17.21. Medline Industries, LP
  • 17.22. Merck & Co., Inc.
  • 17.23. Mylan N.V.
  • 17.24. Nidek Medical Products, Inc.
  • 17.25. Novartis AG
  • 17.26. Orion Corporation
  • 17.27. PARI Pharma GmbH
  • 17.28. Pfizer Inc.
  • 17.29. Sun Pharmaceutical Industries Ltd.
  • 17.30. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTICHOLINERGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTICHOLINERGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTICHOLINERGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BETA AGONISTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BETA AGONISTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BETA AGONISTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL METHYLXANTHINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL METHYLXANTHINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL METHYLXANTHINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NASAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NASAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NASAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL FIRST-LINE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL FIRST-LINE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL FIRST-LINE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SECOND-LINE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SECOND-LINE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SECOND-LINE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL THIRD-LINE AND LATER THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL THIRD-LINE AND LATER THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL THIRD-LINE AND LATER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MONOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MONOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MONOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DUAL THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DUAL THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DUAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INPATIENT CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INPATIENT CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INPATIENT CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL OUTPATIENT CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL OUTPATIENT CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL OUTPATIENT CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HOMECARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HOMECARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HOMECARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 113. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 114. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 115. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 117. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. GCC CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 134. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 135. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 136. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 137. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 138. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. G7 CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 141. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 142. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 143. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 145. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. NATO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 156. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 157. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 158. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 160. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. CANADA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 163. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 165. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 167. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. MEXICO CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 170. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 171. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 172. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 174. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. BRAZIL CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED KINGDOM CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 184. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 186. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 188. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. GERMANY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 191. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 192. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 193. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 195. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. FRANCE CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 198. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 200. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 201. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 202. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. RUSSIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 205. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 207. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 208. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 209. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 211. ITALY CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 212. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 213. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 214. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 216. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. SPAIN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 220. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 221. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 222. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 226. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 228. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 229. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 230. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. INDIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 233. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 235. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 236. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 237. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 238. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 239. JAPAN CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 240. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 241. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 242. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 244. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 246. AUSTRALIA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)
  • TABLE 247. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 248. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 249. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 250. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY THERAPY LINE, 2018-2032 (USD MILLION)
  • TABLE 251. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY REGIMEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. SOUTH KOREA CHRONIC OBSTRUCTIVE PULMONARY DISEASE TREATMENT MARKET SIZE, BY CARE SETTING, 2018-2032 (USD MILLION)